OraSure Technologies (OSUR) Projected to Post Quarterly Earnings on Tuesday

Key Points

• OraSure Technologies (OSUR) is set to release its Q2 2025 earnings after the market closes on August 5th, with analysts estimating a loss of ($0.15) per share and revenue of $30.52 million.
• The stock opened at $3.35, with a one-year range between $2.36 and $4.92, reflecting a market capitalization of $250.58 million.
• Institutional investors hold approximately 93.50% of OraSure's stock, indicating strong interest from large investors, including significant increases in stakes by firms like AQR Capital Management.

OraSure Technologies (NASDAQ:OSUR - Get Free Report) is anticipated to release its Q2 2025 earnings data after the market closes on Tuesday, August 5th. Analysts expect OraSure Technologies to post earnings of ($0.15) per share and revenue of $30.52 million for the quarter.

OraSure Technologies Stock Down 5.3%

OSUR traded down $0.17 on Friday, hitting $3.01. The company had a trading volume of 928,277 shares, compared to its average volume of 779,767. The company has a market cap of $225.15 million, a PE ratio of -7.17 and a beta of 0.45. OraSure Technologies has a 12-month low of $2.36 and a 12-month high of $4.92. The business's fifty day simple moving average is $3.02 and its 200 day simple moving average is $3.24.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Evercore ISI reiterated an "in-line" rating and issued a $3.00 price target on shares of OraSure Technologies in a report on Monday, May 19th. Wall Street Zen upgraded OraSure Technologies from a "sell" rating to a "hold" rating in a report on Saturday, May 17th.

Hedge Funds Weigh In On OraSure Technologies

Hedge funds have recently made changes to their positions in the company. Amundi acquired a new position in shares of OraSure Technologies in the 1st quarter valued at $47,000. Envestnet Asset Management Inc. grew its position in OraSure Technologies by 32.7% during the 2nd quarter. Envestnet Asset Management Inc. now owns 33,018 shares of the medical instruments supplier's stock worth $99,000 after purchasing an additional 8,133 shares during the period. NewEdge Advisors LLC grew its position in OraSure Technologies by 32,595.9% during the 1st quarter. NewEdge Advisors LLC now owns 47,736 shares of the medical instruments supplier's stock worth $161,000 after purchasing an additional 47,590 shares during the period. Empowered Funds LLC grew its position in OraSure Technologies by 7.2% during the 1st quarter. Empowered Funds LLC now owns 405,216 shares of the medical instruments supplier's stock worth $1,366,000 after purchasing an additional 27,310 shares during the period. Finally, AQR Capital Management LLC grew its position in OraSure Technologies by 48.3% during the 1st quarter. AQR Capital Management LLC now owns 1,041,875 shares of the medical instruments supplier's stock worth $3,511,000 after purchasing an additional 339,493 shares during the period. 93.50% of the stock is owned by institutional investors and hedge funds.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.